このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

HIT on Hypoglycaemic Risk in T1D

2021年9月10日 更新者:Sam Shepherd、Liverpool John Moores University

Can High Intensity Interval Training Reduce Fear of Hypoglycaemia and Improve Glycaemic Control in People With Type 1 Diabetes?

There is clear evidence that regular exercise improves wellbeing and reduces the risk of diabetes related complications in people with type 1 diabetes. However, many people with type 1 diabetes do not exercise regularly. The primary reason for this is fear of hypoglycaemia and loss of glycaemic control associated with exercise. This loss of glycaemic control is associated with traditional moderate intensity continous aerobic exercise advocated in the guidelines for exercise in people with type 1 diabetes. Recent work (unpublished) from our lab suggests high intensity interval training (HIT) may reduce the risk of hypoglycaemia in people with type 1 diabetes, however stronger evidence is needed before firm conclusions can be drawn.

Therefore, the aim of this study is to determine the effects of HIT on glycaemic control in people with type 1 diabetes compared to no exercise and traditional moderate intensity continous exercise.

24 people with type 1 diabetes will be recruited to complete a randomised counterbalanced cross over study comparing 3x 2-week interventions periods. During these intervention periods participant will maintain their habitual lifestyle but complete either no exercise (control), traditional moderate intensity continous exercise or high intensity interval training. Throughout the intervention periods participants glycaemic control will be monitored using a flash glucose monitor.

調査の概要

詳細な説明

Recruitment 24 people with type 1 diabetes (T1D) will be recruited through local advertising, e.g. within the Liverpool Type 1 Diabetes (LIVT1D) Group.

Protocol The study will use a randomised counterbalanced crossover design, whereby participants will complete 3x 2-week intervention periods; control (no exercise), moderate intensity continous training (MICT) and high intensity interval training (HIT).

Intervention period Participants will complete 3x 2-week intervention periods identical in all respects except for the type of exercise completed.

The day before each intervention period participants will attend the lab at Liverpool John Moores University to have an Abbot Freestyle Libre® flash glucose monitor inserted. To access the data participants will be provide with a "Reader" in "masked" mode, ensuring the participant cannot see the data produced. The Reader will also be used to record time of exercise, insulin doses and blood glucose. Finally, participants will be provided with an activity monitor (Actigraph®) for the duration of the intervention. Participants will also be familiarised to the type of exercise being performed.

In Addition, before the first intervention period participants will also be asked to download MyFitnessPal® to record their daily food intake. An anonymous login email address and password will be given to the participant for access to this App and associated website. A 1ml finger prick blood sample will also be taken on this first visit.

Participants will then complete the 2-week intervention period. During this period participants will be asked to maintain their habitual lifestyle, but only complete the exercise prescribed by the research team (HIT or MICT), or no exercise during the control intervention. Participants will be asked to exercise on day 1, 3, 6, 8, 10 and 13 of the intervention period. Exercise will be completed at any time, but must not be performed following an overnight fast. Participants will be asked to record their blood glucose immediately before and after exercise and 2h post exercise using a finger stick blood sample and automated glucose reader. If participants need to take additional carbohydrates to adjust blood glucose following exercise the investigators will also ask for this to be recorded (what was consumed and time after exercise) using a note in the MyFitnessPal app. Participants will record all insulin doses, time of exercise and food intake for the duration of the intervention period.

Training MICT: Participants will be asked to complete 30 minutes of continuous exercise. Participants will be able to choose any form of exercise (e.g. running or cycling) as long as it is continous in nature. During exercise participants will be asked to maintain a heart rate between 60-70% of their predicted maximum (220-age).

HIT: Participants will be provided with a training guide containing information on the exercises. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest. During the intervals participants will be advised to reach a heart rate of approx. 80% of their predicted maximum heart rate (220-age). The 1 minute interval will be split between 2 consecutive 30 second exercises. The research team have a library of 18 exercises, with 9 suggested exercise pairs. Participants will be advised to complete 6 intervals during each session.

Participants will complete training in a place of their choosing. If requested participants will be able to train in the labs at LJMU.

Participants will be given a polar H7/10 Bluetooth heart rate monitor. Participants will be advised to wear this monitor during all training sessions. The monitor will provide a measure of training intensity and compliance with the suggested heart rate and training programme.

Participants will be asked to download the App PolarBeat to their smartphone. This App will be used to monitor heart rate during the training sessions. In addition, participants will be given a login email address and password for PolarFlow (www.polar.flow.com), a cloud storage site run by Polar for the storage and analysis of heart rate data. All heart rate data measured during training sessions will be uploaded to Polar Flow. This will allow the research team to investigate training intensity achieved during all sessions.

Safety Subjects will be asked to check their blood glucose level to ensure it is safe to exercise. The investigators will use the guidelines that are currently used in a national study of exercise for patients with type 1 diabetes (EXTOD - see attached leaflet). Blood glucose will be checked immediately following exercise and corrected with fast acting carbohydrates if low. The investigators will also advise the subjects to check their glucose level before bed, and if necessary in the early hours of the morning (through setting an alarm clock) if this is required.

Flash Glucose Monitoring Analysis 9 key metrics of glycaemic control will be assessed, reported in 3 time blocks (sleep 00:00-06:00, wake 06:00- 00:00 and 24h 00:00- 00:00): 1) mean glucose, 2) % of time in level 2 hypoglycaemia (<3.0mmol/L), 3) % of time in level 1 hypoglycaemia (3.0-3.9mmol/L), 4) % of time in target range (3.9-10.0mmol/L), 5) % of time in level 1 hyperglycaemia (10.0-13.9mmol/L), 6) % of time in level 2 hyperglycaemia (>13.9mmol/L), 7) glycaemic variability, reported as CV and SD, 8) episodes of hypoglycaemia and hyperglycaemia and 9) area under the curve of episodes of hypoglycaemia and hyperglycaemia.

研究の種類

介入

入学 (実際)

24

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Liverpool、イギリス、L33AF
        • Matthew Cocks

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~55年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • T1D diagnosis more than 6 months ago
  • Using a basal bolus insulin regime or insulin pump therapy
  • BMI ≤ 32 kg.m-2

Exclusion Criteria:

  • Pregnancy (or planning pregnancy)
  • Disability preventing participation in an exercise regime
  • Angina
  • Autonomic neuropathy
  • Medication that affects heart rate (this will affect estimation of fitness)
  • Major surgery planned within 6 weeks of study
  • Uncontrolled blood pressure
  • Significant history of hyperglycaemia
  • History of severe hypoglycaemia requiring third party assistance within the last 3 months
  • Severe non-proliferative and unstable proliferative retinopathy

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
介入なし:コントロール
参加者は習慣的なライフスタイルを続けますが、2週間運動を行いません
アクティブコンパレータ:中強度の連続トレーニング
参加者は、2週間の介入期間中に中程度の強度の連続トレーニングを完了します
参加者は、2 週間の介入期間中に中程度の強度の連続トレーニングの 6 セッションを完了します。 参加者は、30 分間の連続エクササイズを完了するよう求められます。
実験的:高強度インターバルトレーニング
参加者は、2週間の介入期間中に高強度インターバルトレーニングを完了します
参加者は、2 週間の介入期間中に高強度インターバル トレーニングの 6 セッションを完了します。 このプログラムでは、1 分間の休憩を挟んで、1 分間の単純なその場での動きを繰り返します。

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Severe hypoglycaemia (using continuous glucose monitoring)
時間枠:Over a 2 week intervention period
Number of severe hypoglycaemic events (<3mmol/l) during the 2 week intervention period
Over a 2 week intervention period

二次結果の測定

結果測定
メジャーの説明
時間枠
Mean glucose (using continuous glucose monitoring)
時間枠:Over a 2 week intervention period
mean glucose level over 2 week recording period
Over a 2 week intervention period
% of time in level 2 hypoglycaemia (<3.0mmol/L) (using continuous glucose monitoring)
時間枠:Over a 2 week intervention period
% of time in level 2 hypoglycaemia (<3.0mmol/L) over 2 week recording period
Over a 2 week intervention period
% of time in level 1 hypoglycaemia (3.0-3.9mmol/L) (using continuous glucose monitoring)
時間枠:Over a 2 week intervention period
% of time in level 1 hypoglycaemia (3.0-3.9mmol/L) over 2 week recording period
Over a 2 week intervention period
% of time in target range (3.9-10.0mmol/L) (using continuous glucose monitoring)
時間枠:Over a 2 week intervention period
% of time in target range (3.9-10.0mmol/L) over 2 week recording period
Over a 2 week intervention period
% of time in level 1 hyperglycaemia (10.0-13.9mmol/L) (using continuous glucose monitoring)
時間枠:Over a 2 week intervention period
% of time in level 1 hyperglycaemia (10.0-13.9mmol/L) over 2 week recording period
Over a 2 week intervention period
% of time in level 2 hyperglycaemia (>13.9mmol/L) (using continuous glucose monitoring)
時間枠:Over a 2 week intervention period
% of time in level 2 hyperglycaemia (>13.9mmol/L) over 2 week recording period
Over a 2 week intervention period
glycaemic variability (using continuous glucose monitoring)
時間枠:2 weeks
Standard deviation in glucose concentrations obtained over a 2 week period using a continuous glucose monitoring device.
2 weeks
area under the curve of episodes of hypoglycaemia and hyperglycaemia
時間枠:Over a 2 week intervention period
area under the curve of episodes of hypoglycaemia and hyperglycaemia 2 week recording period
Over a 2 week intervention period

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2018年10月1日

一次修了 (実際)

2019年8月1日

研究の完了 (実際)

2019年8月1日

試験登録日

最初に提出

2018年6月25日

QC基準を満たした最初の提出物

2021年9月10日

最初の投稿 (実際)

2021年9月14日

学習記録の更新

投稿された最後の更新 (実際)

2021年9月14日

QC基準を満たした最後の更新が送信されました

2021年9月10日

最終確認日

2021年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

No individual participant data will be shared outside the research team. Anonymised group data will be presented in research articles and presentations

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する